New and improved strategies for the treatment of gout

International Journal of Nephrology and Renovascular Disease

Volumn 3, Issue , 2010, Pages 145-166

  Dubchak, Natalie ^a   Falasca, Gerald F ^a  

^a Department of Anesthesiology   (United States)

Author keywords

Allopurinol; Colchicine; Febuxostat; Hyperuricemia; Metabolic syndrome; Tophi

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; APREMILAST; ASCORBIC ACID; BENZBROMARONE; CANAKINUMAB; CELECOXIB; COLCHICINE; COLCRYS; CORTICOSTEROID; CYCLOSPORIN; FEBUXOSTAT; FENOFIBRATE; INDOMETACIN; LOSARTAN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; ORGANIC ANION TRANSPORTER; OXIPURINOL; PEGLOTICASE; PLACEBO; PREDNISONE; PROBENECID; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; ROFECOXIB; STEROID; TRANILAST; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; URATE TRANSPORTER 1;

ACUTE DISEASE; BONE MARROW DEPRESSION; CARDIOVASCULAR DISEASE; CHERRY; CHRONIC KIDNEY DISEASE; COMPUTER ASSISTED TOMOGRAPHY; DEHYDRATION; DIAGNOSTIC IMAGING; DIARRHEA; DIETARY INTAKE; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECHOGRAPHY; EOSINOPHILIA; EPIDERMOLYSIS; EXFOLIATIVE DERMATITIS; FAMILIAL COLD AUTOINFLAMMATORY SYNDROME; FEVER; FRUIT JUICE; GASTROINTESTINAL SYMPTOM; GOUT; HEPATITIS; HUMAN; HYPERSENSITIVITY REACTION; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPERURICEMIA; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LEUKOCYTOSIS; LIVER FAILURE; LOW DRUG DOSE; METABOLIC ACIDOSIS; METABOLIC SYNDROME X; MUCKLE WELLS SYNDROME; MYOPATHY; NEPHROLITHIASIS; NEUROMUSCULAR DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOARTHRITIS; PATHOPHYSIOLOGY; POLYNEUROPATHY; RASH; RECOMMENDED DRUG DOSE; RECURRENT DISEASE; REVIEW; RHABDOMYOLYSIS; RISK FACTOR; SIDE EFFECT; SINGLE DRUG DOSE; VITAMIN SUPPLEMENTATION;

EID: 79251498047     PISSN: None     EISSN: 11787058     Source Type: Book Series    
DOI: None     Document Type: Review

References (238)

1. Choi HK, Mount DB, Reginato AM. Pathogenesis of gout. Ann Intern Med. 2005;143(7):499-516.
2. Choi HK, Curhan G. Gout: epidemiology and lifestyle choices. Curr Opin Rheumatol. 2005;17(3):341-345.
3. Nriagu JO. Saturnine gout among Roman aristocrats. Did lead poisoning contribute to the fall of the Empire? N Engl J Med. 1983;308(11): 660-663.
4. Healey LA. Port wine and the gout. Arthritis Rheum. 1975;18 Suppl 6: 659-662.
5. Steinbock RT. Lead ingestion in history. N Engl J Med. 1979; 301(5):277.
6. Hak AE, Choi HK. Lifestyle and gout. Curr Opin Rheumatol. 2008;20(2): 179-186.
7. Saag KG, Choi H. Epidemiology, risk factors, and lifestyle modifcations for gout. Arthritis Res Ther. 2006; 8 Suppl 1:S2.
8. Saag KG, Mikuls TR. Recent advances in the epidemiology of gout. Curr Rheumatol Rep. 2005;7(3):235-241.
9. Kahn AM. Effect of diuretics on the renal handling of urate. Semin Nephrol. 1988;8(3):305-314.
10. Caspi D, Lubart E, Graff E, Habot B, Yaron M, Segal R. The effect of mini-dose aspirin on renal function and uric acid handling in elderly patients. Arthritis Rheum. 2000;43(1):103-108.
11. Schumacher HR Jr, Becker MA, Wortmann RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008;59(11): 1540-1548.
12. Sundy JS, Becker MA, Baraf HS, et al. Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: Results of a phase II randomized study. Arthritis Rheum. 2008;58(9):2882-2891.
13. Sherman MR, Saifer MG, Perez-Ruiz F. PEG-uricase in the management of treatment-resistant gout and hyperuricemia. Adv Drug Deliv Rev. 2008;60(1):59-68.
14. Farkouh ME, Greenberg B P. An evidence-based review of the cardiovascular risks of nonsteroidal anti-infammatory drugs. Am J Cardiol. 2009;103(9):1227-1237.
15. Edwards NL. The role of hyperuricemia and gout in kidney and cardiovascular disease. Cleve Clin J Med. 2008; 75 Suppl 5:S13-S16.
16. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008;359(17):1811-1821.
17. Schlesinger N, Dalbeth N, Perez-Ruiz F. Gout - what are the treatment options? Expert Opin Pharmacother. 2009;10(8):1319-1328.
18. Thiele RG, Schlesinger N. Ultrasonography shows disappearance of monosodium urate crystal deposition on hyaline cartilage after sustained normouricemia is achieved. Rheumatol Int. 2010;30(4):495-503.
19. Perez-Ruiz F, Dalbeth N, Urresola A, de Miguel E, Schlesinger N. Gout. Imaging of gout: findings and utility. Arthritis Res Ther. 2009; 11(3):232.
20. Lee SJ, Hirsch JD, Terkeltaub R, et al. Perceptions of disease and health-related quality of life among patients with gout. Rheumatology (Oxford). 2009;48(5):582-586.
21. Singh JA. Quality of life and quality of care for patients with gout. Curr Rheumatol Rep. 2009;11(2):154-160.
22. Singh JA, Strand V. Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisation in US veterans. Ann Rheum Dis. 2008;67(9):1310-1316.
23. Roddy E, Zhang W, Doherty M. Is gout associated with reduced quality of life? A case-control study. Rheumatology (Oxford). 2007;46(9): 1441-1444.
24. Winzenberg T, Buchbinder R; Cochrane Musculoskeletal Group review: acute gout. Steroids or NSAIDs? Let this overview from the Cochrane Group help you decide what's best for your patient. J Fam Pract. 2009;58(7):E1-E4.
25. Kim SY, Choi HK. Gout and quality of life. J Rheumatol. 2009;36(5): 865-868.
26. Shulten P, Thomas J, Miller M, Smith M, Ahern M. The role of diet in the management of gout: a comparison of knowledge and attitudes to current evidence. J Hum Nutr Diet. 2009;22(1):3-11.
27. Weaver AL. Epidemiology of gout. Cleve Clin J Med. 2008; 75 Suppl 5: S9-S12.
28. Campion E W, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med. 1987 Mar;82(3):421-426.
29. Marinello E, Riario-Sforza G, Marcolongo R. Plasma follicle-stimulating hormone, luteinizing hormone, and sex hormones in patients with gout. Arthritis Rheum. 1985;28(2):127-131.
30. Rosen R, Tomer Y, Carel R, Weinberger A. Serum 17-beta-estradiol and testosterone levels in asymptomatic hyperuricaemic men. Clin Rheumatol. 1994;13(2):219-223.
31. Rho YH, Choi SJ, Lee YH, et al. The prevalence of metabolic syndrome in patients with gout: a multicenter study. J Korean Med Sci. 2005;20(6):1029-1033.
32. Onat A, Uyarel H, Hergenc G, et al. Serum uric acid is a determinant of metabolic syndrome in a population-based study. Am J Hypertens. 2006;19(10):1055-1062.
33. Takahashi S, Yamamoto T, Moriwaki Y, Tsutsumi Z, Higashino K. Impaired lipoprotein metabolism in patients with primary gout - infuence of alcohol intake and body weight. Br J Rheumatol. 1994;33(8): 731-734.
34. Genelhu VA, Celoria BM, Duarte S F, Cabello PH, Francischetti EA. Not all obese subjects of multiethnic origin are at similar risk for developing hypertension and type 2 diabetes. Eur J Intern Med. 2009;20(3): 289-295.
35. Choi HK. Diet, alcohol, and gout: how do we advise patients given recent developments? Curr Rheumatol Rep. 2005;7(3):220-226.
36. Torralba T P, Bayani-Sioson PS. The Filipino and gout. Semin Arthritis Rheum. 1975;4(4):307-320.
37. Kaplan H, Klatskin G. Sarcoidosis, psoriasis, and gout: syndrome or coincidence? Yale J Biol Med. 1960;32:335-352.
38. Yu TF. Secondary gout associated with myeloproliferative diseases. Arthritis Rheum. 1965;8(5):765-771.
39. Brutsche RL, Doerner AA. Chronic lymphocytic leukemia; report of a case with marked uric acid crystalluria. AMA Arch Intern Med. 1956; 97(6):817-819.
40. Ludwig GD. Saturnine gout; a secondary type of gout. AMA Arch Intern Med. 1957;100(5):802-812.
41. Kang EH, Lee EY, Lee YJ, Song Y W, Lee EB. Clinical features and risk factors of postsurgical gout. Ann Rheum Dis. 2008;67(9):1271-1275.
42. Raj JM, Sudhakar S, Sems K, Carlson RW. Arthritis in the intensive care unit. Crit Care Clin. 2002;18(4):767-780.
43. Kurtzman NA. Coexistent sarcoidosis and gout. J Lancet. 1965;85: 195-196.
44. Rubin MR, Silverberg SJ. Rheumatic manifestations of primary hyper-parathyroidism and parathyroid hormone therapy. Curr Rheumatol Rep. 2002;4(2):179-185.
45. Kang HC, Chung DE, Kim DW, Kim HD. Early- and late-onset complications of the ketogenic diet for intractable epilepsy. Epilepsia. 2004;45(9):1116-1123.
46. Cameron JS, Simmonds HA. Hereditary hyperuricemia and renal disease. Semin Nephrol. 2005;25(1):9-18.
47. Kamatani N, Yamanaka H, Totokawa S, Kashiwazaki S, Higurashi M. Down syndrome with coexistent gout: report of six patients and possible reasons for the scarcity of descriptions of this association. Ann Rheum Dis. 1996;55(9):649-650.
48. Saigal R, Chakraborty A, Yadav RN, Prashant RK. Partial HPRT defciency (Kelley-Seegmiller syndrome). J Assoc Physicians India. 2006;54:49-52.
49. Nyhan WL. Inherited hyperuricemic disorders. Contrib Nephrol. 2005;147:22-34.
50. Nakagawa T, Hu H, Zharikov S, et al. A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol. 2006;290(3):F625-F631.
51. Saglam F, Celik A, Sarioglu S, et al. Hyperuricemia infuences chronic cyclosporine nephropathy. Transplant Proc. 2008;40(1):167-170.
52. White M, Haddad H, Leblanc MH, et al. Conversion from cyclosporine microemulsion to tacrolimus-based immunoprophylaxis improves cholesterol profle in heart transplant recipients with treated but persistent dyslipidemia: the Canadian multicentre randomized trial of tacrolimus vs cyclosporine microemulsion. J Heart Lung Transplant. 2005;24(7): 798-809.
53. Noordzij TC, Leunissen KM, van Hooff J P. Renal handling of urate and the incidence of gouty arthritis during cyclosporine and diuretic use. Transplantation. 1991;52(1):64-67.
54. Nakagawa T, Tuttle KR, Short RA, Johnson RJ. Hypothesis: fructose-induced hyperuricemia as a causal mechanism for the epidemic of the metabolic syndrome. Nat Clin Pract Nephrol. 2005;1(2):80-86.
55. Sanchez-Lozada LG, Tapia E, Bautista-Garcia P, et al. Effects of febuxo-stat on metabolic and renal alterations in rats with fructose-induced metabolic syndrome. Am J Physiol Renal Physiol. 2008;294(4):F710-F718.
56. Siu Y P, Leung KT, Tong MK, Kwan TH. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis. 2006;47(1):51-59.
57. White JS. Misconceptions about high-fructose corn syrup: is it uniquely responsible for obesity, reactive dicarbonyl compounds, and advanced glycation endproducts? J Nutr. 2009; 139(6):1219S-1227S.
58. White JS. Straight talk about high-fructose corn syrup: what it is and what it ain't. Am J Clin Nutr. 2008; 88(6):1716S-1721S.
59. Soleimani M. Dietary fructose, salt absorption and hypertension in metabolic syndrome: Toward a new paradigm. Acta Physiol (Oxf). 2010. [Epub ahead of print].
60. Akhavan T, Anderson GH. Effects of glucose-to-fructose ratios in solutions on subjective satiety, food intake, and satiety hormones in young men. Am J Clin Nutr. 2007;86(5):1354-1363.
61. Fessel WJ. Renal outcomes of gout and hyperuricemia. Am J Med. 1979;67(1):74-82.
62. Miranda-Carus E, Mateos FA, Sanz AG, Herrero E, Ramos T, Puig JG. Purine metabolism in patients with gout: the role of lead. Nephron. 1997;75(3):327-335.
63. Feig DI. Uric acid: a novel mediator and marker of risk in chronic kidney disease? Curr Opin Nephrol Hypertens. 2009;18(6):526-530.
64. Edwards NL. The role of hyperuricemia in vascular disorders. Curr Opin Rheumatol. 2009;21(2):132-137.
65. Kang DH, Han L, Ouyang X, et al. Uric acid causes vascular smooth muscle cell proliferation by entering cells via a functional urate transporter. Am J Nephrol. 2005;25(5):425-433.
66. Nakagawa T, Mazzali M, Kang DH, et al. Hyperuricemia causes glom-erular hypertrophy in the rat. Am J Nephrol. 2003;23(1):2-7.
67. Nakagawa T, Kang DH, Ohashi R, et al. Tubulointerstitial disease: role of ischemia and microvascular disease. Curr Opin Nephrol Hypertens. 2003;12(3):233-241.
68. Gibson T, Rodgers V, Potter C, Simmonds HA. Allopurinol treatment and its effect on renal function in gout: a controlled study. Ann Rheum Dis. 1982;41(1):59-65.
69. Avram Z, Krishnan E. Hyperuricaemia - where nephrology meets rheumatology. Rheumatology (Oxford). 2008;47(7):960-964.
70. Whelton A, MacDonald P, Lloyd E, Lademacher C. Benefcial relationship of serum urate (sUA) reduction and estimated glomerular fltration rate (eGFR) improvement/maintenance in hyperuricemic gout subjects treated for up to 5.5 years with febuxostat (FEB) [abstract). 2008 American College of Rheumatology Meeting. San Francisco, CA; 2008.
71. Gaffo AL, Edwards NL, Saag KG. Gout. Hyperuricemia and cardiovascular disease: how strong is the evidence for a causal link? Arthritis Res Ther. 2009;11(4):240.
72. Shah A, Keenan RT. Gout, hyperuricemia, and the risk of cardiovascular disease: cause and effect? Curr Rheumatol Rep. 2010;12(2): 118-124.
73. Roncal CA, Reungjui S, Sanchez-Lozada LG, et al. Combination of captopril and allopurinol retards fructose-induced metabolic syndrome. Am J Nephrol. 2009;30(5):399-404.
74. Nakagawa T, Mazzali M, Kang DH, Sanchez-Lozada LG, Herrera-Acosta J, Johnson RJ. Uric acid - a uremic toxin? Blood Purif. 2006; 24(1):67-70.
75. Masuo K, Kawaguchi H, Mikami H, Ogihara T, Tuck ML. Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension. 2003; 42(4):474-480.
76. Nagahama K, Inoue T, Iseki K, et al. Hyperuricemia as a predictor of hypertension in a screened cohort in Okinawa, Japan. Hypertens Res. 2004;27(11):835-841.
77. Nakanishi N, Okamoto M, Yoshida H, Matsuo Y, Suzuki K, Tatara K. Serum uric acid and risk for development of hypertension and impaired fasting glucose or Type II diabetes in Japanese male offce workers. Eur J Epidemiol. 2003;18(6):523-530.
78. Annemans L, Spaepen E, Gaskin M, et al. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. Ann Rheum Dis. 2008;67(7):960-966.
79. Krishnan E, Kwoh CK, Schumacher HR, Kuller L. Hyperuricemia and incidence of hypertension among men without metabolic syndrome. Hypertension. 2007;49(2):298-303.
80. Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA. 2008;300(8):924-932.
81. Tang Z, Cheng LT, Li H Y, Wang T. Serum uric acid and endothelial dysfunction in continuous ambulatory peritoneal dialysis patients. Am J Nephrol. 2009;29(5):368-373.
82. Bergamini C, Cicoira M, Rossi A, Vassanelli C. Oxidative stress and hyperuricaemia: pathophysiology, clinical relevance, and therapeutic implications in chronic heart failure. Eur J Heart Fail. 2009;11(5): 444-452.
83. Mitsuhashi H, Yatsuya H, Matsushita K, et al. Uric acid and left ventricular hypertrophy in Japanese men. Circ J. 2009;73(4):667-672.
84. Bainbridge SA, von Versen-Hoynck F, Roberts JM. Uric acid inhibits pla-cental system A amino acid uptake. Placenta. 2009;30(2):195-200.
85. Terkeltaub R, Bushinsky DA, Becker MA. Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics. Arthritis Res Ther. 2006; 8 Suppl 1:S4.
86. Benedict JD, Forsham PH, Stetten D Jr. The metabolism of uric acid in the normal and gouty human studied with the aid of isotopic uric acid. J Biol Chem. 1949;181(1):183-193.
87. Campo C, Ruilope LM, Segura J, Rodicio JL, Garcia-Robles R, Garcia-Puig J. Hyperuricemia, low urine urate excretion and target organ damage in arterial hypertension. Blood Press. 2003;12(5-6):277-283.
88. Enomoto A, Kimura H, Chairoungdua A, et al. Molecular identifca-tion of a renal urate anion exchanger that regulates blood urate levels. Nature. 2002;417(6887):447-452.
89. Eraly SA, Vallon V, Rieg T, et al. Multiple organic anion transporters contribute to net renal excretion of uric acid. Physiol Genomics. 2008; 33(2):180-192.
90. Silverman W, Locovei S, Dahl G. Probenecid, a gout remedy, inhibits pannexin 1 channels. Am J Physiol Cell Physiol. 2008;295(3): C761-C767.
91. Enomoto A, Niwa T, Kanai Y, Endou H. Urate transporter and renal hypouricemia. Rinsho Byori. 2003;51(9):892-897.
92. So A, Thorens B. Uric acid transport and disease. J Clin Invest. 2010; 120(6):1791-1799.
93. Lipkowitz MS, Leal-Pinto E, Cohen BE, Abramson RG. Galectin 9 is the sugar-regulated urate transporter/channel UAT. Glycoconj J. 2004;19(7-9):491-498.
94. Choi HK, Zhu Y, Mount DB. Genetics of gout. Curr Opin Rheumatol. 2010;22(2):144-151.
95. Urano W, Taniguchi A, Anzai N, et al. Sodium-dependent phosphate cotransporter type 1 sequence polymorphisms in male patients with gout. Ann Rheum Dis. 2010;69(6):1232-1234.
96. Matsuo H, Takada T, Ichida K, et al. Common defects of ABCG2, a high-capacity urate exporter, cause gout: a function-based genetic analysis in a Japanese population. Sci Transl Med. 2009;1(5):5-11.
97. Cheeseman C. Solute carrier family 2, member 9 and uric acid homeo-stasis. Curr Opin Nephrol Hypertens. 2009;18(5):428-432.
98. Dahan K, Devuyst O, Smaers M, et al. A cluster of mutations in the UMOD gene causes familial juvenile hyperuricemic nephropathy with abnormal expression of uromodulin. J Am Soc Nephrol. 2003;14(11): 2883-2893.
99. Rampoldi L, Caridi G, Santon D, et al. Allelism of MCKD, FJHN and GCKD caused by impairment of uromodulin export dynamics. Hum Mol Genet. 2003;12(24):3369-3384.
100. Storey GD. Alfred Baring Garrod (1819-1907). Rheumatology (Oxford). 2001;40(10):1189-1190.
101. Faires JS, McCarty DJ. Acute arthritis in man and dog after intra-synovial injection of sodium urate crystals. Lancet. 1962;280(7258): 682-685.
102. Pascual E, Jovani V. A quantitative study of the phagocytosis of urate crystals in the synovial fuid of asymptomatic joints of patients with gout. Br J Rheumatol. 1995;34(8):724-726.
103. Simkin PA. Concentration of urate by differential diffusion: a hypothesis for initial urate deposition. Adv Exp Med Biol. 1974;41:547-550.
104. So A. Developments in the scientifc and clinical understanding of gout. Arthritis Res Ther. 2008;10(5):221.
105. Pillinger MH, Keenan RT. Update on the management of hyperuricemia and gout. Bull NYU Hosp Jt Dis. 2008;66(3):231-239.
106. Liote F, Ea HK. Recent developments in crystal-induced infamma-tion pathogenesis and management. Curr Rheumatol Rep. 2007;9(3): 243-250.
107. Reginato AM, Olsen BR. Genetics and experimental models of crystal-induced arthritis. Lessons learned from mice and men: is it crystal clear? Curr Opin Rheumatol. 2007;19(2):134-145.
108. Rose DM, Liu-Bryan R. Innate immunity in triggering and resolution of acute gouty infammation. Curr Rheumatol Rep. 2006;8(3): 209-214.
109. Koopman WJ, Moreland LW. Arthritis and Allied Conditions: A Textbook of Rheumatology. 15th ed. Philadelphia: Lippincott Williams & Wilkins; 2005.
110. Abramson S, Hoffstein ST, Weissmann G. Superoxide anion generation by human neutrophils exposed to monosodium urate. Arthritis Rheum. 1982;25(2):174-180.
111. Terkeltaub RA, Dyer CA, Martin J, Curtiss LK. Apolipoprotein (apo) E inhibits the capacity of monosodium urate crystals to stimulate neutro-phils. Characterization of intraarticular apo E and demonstration of apo E binding to urate crystals in vivo. J Clin Invest. 1991;87(1):20-26.
112. Akahoshi T, Murakami Y, Kitasato H. Recent advances in crystal-induced acute infammation. Curr Opin Rheumatol. 2007;19(2): 146-150.
113. McCarty DJ Jr, Phelps P, Pyenson J. Crystal-induced infammation in canine joints. I. An experimental model with quantifcation of the host response. J Exp Med. 1966;124(1):99-114.
114. Falasca GF, Ramachandrula A, Kelley KA, O'Connor CR, Reginato AJ. Superoxide anion production and phagocytosis of crystals by cultured endothelial cells. Arthritis Rheum. 1993;36(1):105-116.
115. Terkeltaub R, Zachariae C, Santoro D, Martin J, Peveri P, Matsushima K. Monocyte-derived neutrophil chemotactic factor/interleukin-8 is a potential mediator of crystal-induced infammation. Arthritis Rheum. 1991;34(7):894-903.
116. Duff G W, Atkins E, Malawista SE. The fever of gout: urate crystals activate endogenous pyrogen production from human and rabbit mono-nuclear phagocytes. Trans Assoc Am Physicians. 1983;96:234-245.
117. Martin WJ, Walton M, Harper J. Resident macrophages initiating and driving infammation in a monosodium urate monohydrate crystal-induced murine peritoneal model of acute gout. Arthritis Rheum. 2009; 60(1):281-289.
118. Martin WJ, Harper JL. Innate infammation and resolution in acute gout. Immunol Cell Biol. 2010;88(1):15-19.
119. Liu-Bryan R, Scott P, Sydlaske A, Rose DM, Terkeltaub R. Innate immunity conferred by Toll-like receptors 2 and 4 and myeloid differentiation factor 88 expression is pivotal to monosodium urate mono-hydrate crystal-induced infammation. Arthritis Rheum. 2005;52(9): 2936-2946.
120. Ryckman C, Gilbert C, de Medicis R, Lussier A, Vandal K, Tessier PA. Monosodium urate monohydrate crystals induce the release of the proinfammatory protein S100A8/A9 from neutrophils. J Leukoc Biol. 2004;76(2):433-440.
121. Gasse P, Riteau N, Charron S, et al. Uric acid is a danger signal activating NALP3 infammasome in lung injury infammation and fbrosis. Am J Respir Crit Care Med. 2009; 179(10):903-913.
122. Martinon F, Mayor A, Tschopp J. The infammasomes: guardians of the body. Annu Rev Immunol. 2009; 27: 229-265.
123. Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol. 2007;81(1):1-5.
124. Malawista SE, Duff G W, Atkins E, Cheung HS, McCarty DJ. Crystal-induced endogenous pyrogen production. A further look at gouty infammation. Arthritis Rheum. 1985;28(9):1039-1046.
125. Wood DD, Ihrie EJ, Dinarello CA, Cohen PL. Isolation of an interleu-kin-1-like factor from human joint effusions. Arthritis Rheum. 1983; 26(8):975-983.
126. di Giovine FS, Malawista SE, Nuki G, Duff G W. Interleukin 1 (IL 1) as a mediator of crystal arthritis. Stimulation of T cell and synovial fbroblast mitogenesis by urate crystal-induced IL 1. J Immunol. 1987 May 15;138(10):3213-3218.
127. Martinon F, Burns K, Tschopp J. The infammasome: a molecular platform triggering activation of infammatory caspases and processing of proIL-beta. Mol Cell. 2002;10(2):417-426.
128. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 infammasome. Nature. 2006;440(7081):237-241.
129. Sidiropoulos PI, Goulielmos G, Voloudakis GK, Petraki E, Boumpas DT. Infammasomes and rheumatic diseases: evolving concepts. Ann Rheum Dis. 2008;67(10):1382-1389.
130. Franchi L, Eigenbrod T, Munoz-Planillo R, Nunez G. The infam-masome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat Immunol. 2009;10(3): 241-247.
131. Pope RM, Tschopp J. The role of interleukin-1 and the infammasome in gout: implications for therapy. Arthritis Rheum. 2007;56(10): 3183-3188.
132. Liu-Bryan R. Intracellular innate immunity in gouty arthritis: role of NALP3 infammasome. Immunol Cell Biol. 2010;88(1):20-23.
133. Church LD, Cook GP, McDermott MF. Primer: infammasomes and interleukin 1beta in infammatory disorders. Nat Clin Pract Rheumatol. 2008;4(1):34-42.
134. Petrilli V, Martinon F. The infammasome, autoinfammatory diseases, and gout. Joint Bone Spine. 2007;74(6):571-576.
135. Liu-Bryan R, Pritzker K, Firestein GS, Terkeltaub R. TLR2 signaling in chondrocytes drives calcium pyrophosphate dihydrate and monoso-dium urate crystal-induced nitric oxide generation. J Immunol. 2005; 174(8):5016-5023.
136. Liu-Bryan R, Liote F. Monosodium urate and calcium pyrophosphate dihydrate (CPPD) crystals, infammation, and cellular signaling. Joint Bone Spine. 2005;72(4):295-302.
137. Scott P, Ma H, Viriyakosol S, Terkeltaub R, Liu-Bryan R. Engagement of CD14 mediates the infammatory potential of monosodium urate crystals. J Immunol. 2006;177(9):6370-6378.
138. Yagnik DR, Evans BJ, Florey O, Mason JC, Landis RC, Haskard DO. Macrophage release of transforming growth factor beta1 during resolution of monosodium urate monohydrate crystal-induced infammation. Arthritis Rheum. 2004;50(7):2273-2280.
139. Landis RC, Yagnik DR, Florey O, et al. Safe disposal of infam-matory monosodium urate monohydrate crystals by differentiated macrophages. Arthritis Rheum. 2002;46(11):3026-3033.
140. Marcolongo R, Calabria AA, Lalumera M, Gerli R, Alessandrini C, Cavallo G. The "switch-off" mechanism of spontaneous resolution of acute gout attack. J Rheumatol. 1988;15(1):101-109.
141. Schumacher HR Jr. The pathogenesis of gout. Cleve Clin J Med. 2008; 75 Suppl 5:S2-S4.
142. Falasca GF. Metabolic diseases: gout. Clin Dermatol. 2006;24(6): 498-508.
143. ter Borg EJ, Rasker JJ. Gout in the elderly, a separate entity? Ann Rheum Dis. 1987;46(1):72-76.
144. O'Dell JR. Gout in Heberden's nodes. Arthritis Rheum. 1983;26(11): 1413-1414.
145. Molinos Normiella C, Rey Galan C, Medina Villanueva A, Concha Torre A, Menendez Cuervo S. Uric acid as a prognostic marker in critically ill patients. An Esp Pediatr. 2001;55(4):305-309.
146. Weaver J, Somani N, Bauer T W, Piliang M. Simple non-staining method to demonstrate urate crystals in formalin-fxed, paraffn-embedded skin biopsies. J Cutan Pathol. 2009;36(5):560-564.
147. Shidham V, Chivukula M, Basir Z, Shidham G. Evaluation of crystals in formalin-fxed, paraffn-embedded tissue sections for the differential diagnosis of pseudogout, gout, and tumoral calcinosis. Mod Pathol. 2001;14(8):806-810.
148. Perez-Ruiz F, Dalbeth N, Urresola A, de Miguel E, Schlesinger N. Imaging of gout: fndings and utility. Arthritis Res Ther. 2009;11(3):232.
149. Dalbeth N, McQueen FM. Use of imaging to evaluate gout and other crystal deposition disorders. Curr Opin Rheumatol. 2009;21(2): 124-131.
150. Filippucci E, Scire CA, Delle Sedie A, et al. Ultrasound imaging for the rheumatologist. XXV. Sonographic assessment of the knee in patients with gout and calcium pyrophosphate deposition disease. Clin Exp Rheumatol. 2010;28(1):2-5.
151. de Avila Fernandes E, Kubota ES, Sandim GB, Mitraud SA, Ferrari AJ, Fernandes AR. Ultrasound features of tophi in chronic tophaceous gout. Skeletal Radiol. 2010. [Epub ahead of print].
152. Thiele RG, Schlesinger N. Diagnosis of gout by ultrasound. Rheuma-tolog y (Oxford). 2007;46(7):1116-1121.
153. Carter JD, Kedar R P, Anderson SR, et al. An analysis of MRI and ultrasound imaging in patients with gout who have normal plain radiographs. Rheumatology (Oxford). 2009;48(11):1442-1446.
154. Kunkel G, Kaeley G, Thiele R. Comment on: an analysis of MRI and ultrasound imaging in patients with gout who have normal plain radiographs. Rheumatology (Oxford). 2010;49(5):1022-1023; author reply 1023-1024.
155. Neogi T, Hunter DJ, Chaisson CE, Allensworth-Davies D, Zhang Y. Frequency and predictors of inappropriate management of recurrent gout attacks in a longitudinal study. J Rheumatol. 2006;33(1): 104-109.
156. Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS, Davis M W. High versus low dosing of oral colchicine for early acute gout fare: Twenty-four-hour outcome of the frst multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose- comparison colchicine study. Arthritis Rheum. 2010;62(4):1060-1068.
157. Pharma U. Colcrys Offcial Prescribing Information. 2010 May: Offcial Prescribing Information. http://colcrys.com/assets/pdf/COLCRYS_Full_Prescribing_Information.pdf. Accessed 2010 Aug 28.
158. Molad Y. Update on colchicine and its mechanism of action. Curr Rheumatol Rep. 2002;4(3):252-256.
159. Chen YJ, Huang SM, Liu CY, Ye h PH, Tsai TH. Hepatobiliary excretion and enterohepatic circulation of colchicine in rats. Int J Pharm. 2008;350(1-2):230-239.
160. Montseny JJ, Meyrier A, Gherardi RK. Colchicine toxicity in patients with chronic renal failure. Nephrol Dial Transplant. 1996;11(10): 2055-2058.
161. Schiff D, Drislane F W. Rapid-onset colchicine myoneuropathy. Arthritis Rheum. 1992;35(12):1535-1536.
162. Fiehn C, Zeier M. Successful treatment of chronic tophaceous gout with infiximab (Remicade). Rheumatol Int. 2006;26(3):274-276.
163. Tausche AK, Richter K, Grassler A, Hansel S, Roch B, Schroder HE. Severe gouty arthritis refractory to anti-infammatory drugs: treatment with anti-tumour necrosis factor alpha as a new therapeutic option. Ann Rheum Dis. 2004;63(10):1351-1352.
164. Meng ZH, Hudson A P, Schumacher HR Jr, Baker J F, Baker DG. Monosodium urate, hydroxyapatite, and calcium pyrophosphate crystals induce tumor necrosis factor-alpha expression in a mononuclear cell line. J Rheumatol. 1997;24(12):2385-2388.
165. di Giovine FS, Malawista SE, Thornton E, Duff G W. Urate crystals stimulate production of tumor necrosis factor alpha from human blood monocytes and synovial cells. Cytokine mRNA and protein kinetics, and cellular distribution. J Clin Invest. 1991;87(4):1375-1381.
166. So A, de Smedt T, Revaz S, Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther. 2007;9(2):R28.
167. Singh D, Huston KK. IL-1 inhibition with anakinra in a patient with refractory gout. J Clin Rheumatol. 2009;15(7):366.
168. Gratton SB, Scalapino KJ, Fye KH. Case of anakinra as a steroid-sparing agent for gout infammation. Arthritis Rheum. 2009;61(9): 1268-1270.
169. Terkeltaub R, Sundy JS, Schumacher HR, et al. The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study. Ann Rheum Dis. 2009;68(10):1613-1617.
170. So A, de Meulemeester M, Pikhlak A, et al. Canakinumab for the treatment of acute fares in diffcult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study. Arthritis Rheum. 2010; 62(10):3064-3076.
171. Study of Tranilast Alone or in Combination With Allopurinol in Subjects With Hyperuricemia. 2010; http://clinicaltrials.gov/ct2/show/NCT01052987?intr=Tranilast&rank=2. Accessed 2010 Sep 1.
172. Higgs G. Is PDE4 too diffcult a drug target? Curr Opin Investig Drugs. 2010;11(5):495-498.
173. Apremilast Therapy for Acute Gouty Arthritis. 2010; http://clinicaltrials.gov/ct2/show/NCT00997581?term=apremilast&rank=11. Accessed 2010 Sep 1.
174. Favre L, Glasson P, Riondel A, Vallotton MB. Interaction of diuretics and non-steroidal anti-infammatory drugs in man. Clin Sci (Lond). 1983;64(4):407-415.
175. Favre L, Glasson P, Vallotton MB. Reversible acute renal failure from combined triamterene and indomethacin: a study in healthy subjects. Ann Intern Med. 1982;96(3):317-320.
176. Varughese GI, Varghese AI. Colchicine myoneuropathy: the role of rhabdomyolysis. Nephrology (Carlton). 2006; 11(5):481-482; author reply 482.
177. Lai IC, Cheng CY, Chen HH, Chen WY, Chen PY. Colchicine myo-neuropathy in chronic renal failure patients with gout. Nephrology (Carlton). 2006;11(2):147-150.
178. Kuncl RW, Duncan G, Watson D, Alderson K, Rogawski MA, Peper M. Colchicine myopathy and neuropathy. N Engl J Med. 1987; 316(25):1562-1568.
179. Uloric Full Prescribing Information. 2009; http://general.takedapharm.com/content/file/pi.pdf?applicationcode=6C7C39D8-5D09-453B-BF30-696A4AB88E62&FileTypeCode=ULORICPI. Accessed 2010 Aug 30.
180. Kissin E Y, Nishio J, Yang M, et al. Self-directed learning of basic musculoskeletal ultrasound among rheumatologists in the United States. Arthritis Care Res (Hoboken). 2010;62(2):155-160.
181. Filippucci E, Riveros MG, Georgescu D, Salaff F, Grassi W. Hyaline cartilage involvement in patients with gout and calcium pyrophosphate deposition disease. An ultrasound study. Osteoarthritis Cartilage. 2009;17(2):178-181.
182. Choi HK. A prescription for lifestyle change in patients with hyperu-ricemia and gout. Curr Opin Rheumatol. 2010;22(2):165-172.
183. Doherty M. New insights into the epidemiology of gout. Rheumatology (Oxford). 2009;48 Suppl 2:ii2-ii8.
184. Cutler DM, Glaeser EL, Shapiro JM. Why have Americans become more obese? J Econ Perspect. 2003;17:93-118.
185. Statistics Related to Overweight and Obesity NIH Publication Number 04-4158. 2010; http://win.niddk.nih.gov/statistics/. Accessed 2010 Aug 1.
186. Choi HK, Atkinson K, Karlson E W, Curhan G. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study. Arch Intern Med. 2005;165(7): 742-748.
187. Choi J W, Ford ES, Gao X, Choi HK. Sugar-sweetened soft drinks, diet soft drinks, and serum uric acid level: The Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2008;59(1): 109-116.
188. Choi HK, Curhan G. Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. BMJ. 2008;336(7639): 309-312.
189. Schlesinger N. Dietary factors and hyperuricaemia. Curr Pharm Des. 2005;11(32):4133-4138.
190. Kerndt PR, Naughton JL, Driscoll CE, Loxterkamp DA. Fasting: the history, pathophysiology and complications. West J Med. 1982;137(5): 379-399.
191. Choi HK, Atkinson K, Karlson E W, Willett W, Curhan G. Alcohol intake and risk of incident gout in men: a prospective study. Lancet. 2004;363(9417):1277-1281.
192. Jacob RA, Spinozzi GM, Simon VA, et al. Consumption of cherries lowers plasma urate in healthy women. J Nutr. 2003;133(6): 1826-1829.
193. Howatson G, McHugh M P, Hill JA, et al. Infuence of tart cherry juice on indices of recovery following marathon running. Scand J Med Sci Sports. 2009. [Epub ahead of print].
194. Kelley DS, Rasooly R, Jacob RA, Kader AA, Mackey BE. Consumption of Bing sweet cherries lowers circulating concentrations of infammation markers in healthy men and women. J Nutr. 2006;136(4): 981-986.
195. USDA National Nutrient Database for Standard Reference. Nutrient Data Laboratory Home Page, http://www.ars.usda.gov/ba/bhnrc/ndl. US Department of Agriculture; 2010. http://www.ars.usda.gov/ba/bhnrc/ndl. Accessed 2010 Oct 8.
196. Blau LW. Cherry diet control for gout and arthritis. Tex Rep Biol Med. 1950;8(3):309-311.
197. Stein HB, Hasan A, Fox IH. Ascorbic acid-induced uricosuria. A consequency of megavitamin therapy. Ann Intern Med. 1976;84(4): 385-388.
198. Choi HK, Gao X, Curhan G. Vitamin C intake and the risk of gout in men: a prospective study. Arch Intern Med. 2009;169(5):502-507.
199. Gao X, Curhan G, Forman J P, Ascherio A, Choi HK. Vitamin C intake and serum uric acid concentration in men. J Rheumatol. 2008;35(9): 1853-1858.
200. McGill NW. Gout and other crystal-associated arthropathies. Baillieres Best Pract Res Clin Rheumatol. 2000;14(3):445-460.
201. Sarawate CA, Brewer KK, Yang W, et al. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc. 2006;81(7):925-934.
202. Riedel AA, Nelson M, Wallace K, Joseph-Ridge N, Cleary M, Fam AG. Prevalence of Comorbid Conditions and Prescription Medication Use Among Patients With Gout and Hyperuricemia in a Managed Care Setting. J Clin Rheumatol. 2004;10(6):308-314.
203. Riedel AA, Nelson M, Joseph-Ridge N, Wallace K, MacDonald P, Becker M. Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims. J Rheumatol. 2004;31(8):1575-1581.
204. Reinders MK, Haagsma C, Jansen TL, et al. A randomised controlled trial on the effcacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout. Ann Rheum Dis. 2009;68(6):892-897.
205. Dalbeth N, Stamp L. Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events. Semin Dial. 2007;20(5):391-395.
206. Shalom R, Rimbroth S, Rozenman D, Markel A. Allopurinol-induced recurrent DRESS syndrome: pathophysiology and treatment. Ren Fail. 2008;30(3):327-329.
207. Fam AG, Lewtas J, Stein J, Paton T W. Desensitization to allopurinol in patients with gout and cutaneous reactions. Am J Med. 1992;93(3): 299-302.
208. Lee SS, Lin H Y, Wang SR, Tsai Y Y. Allopurinol hypersensitivity syndrome. Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi. 1994;27(3):140-147.
209. Lupton G P, Odom RB. The allopurinol hypersensitivity syndrome. J Am Acad Dermatol. 1979;1(4):365-374.
210. Roujeau JC, Kelly J P, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995;333(24):1600-1607.
211. Markel A. Allopurinol-induced DRESS syndrome. Isr Med Assoc J. 2005;7(10):656-660.
212. Hung SI, Chung WH, Liou LB, et al. HLA-B&z.ast;5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A. 2005;102(11):4134-4139.
213. ® Official Prescribing Information. 2003; http://www.prometheuspatients.com/PDF/Zyloprim.pdf. Accessed 2010 Aug 30.
214. Chao J, Terkeltaub R. A critical reappraisal of allopurinol dosing, safety, and effcacy for hyperuricemia in gout. Curr Rheumatol Rep. 2009;11(2):135-140.
215. Gaffo AL, Saag KG. Management of hyperuricemia and gout in CKD. Am J Kidney Dis. 2008;52(5):994-1009.
216. Murrell GA, Rapeport WG. Clinical pharmacokinetics of allopurinol. Clin Pharmacokinet. 1986;11(5):343-353.
217. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insuffciency. Am J Med. 1984;76(1):47-56.
218. Bellamy N, Gilbert JR, Brooks PM, Emmerson BT, Campbell J. A survey of current prescribing practices of antiinfammatory and urate lowering drugs in gouty arthritis in the province of Ontario. J Rheumatol. 1988;15(12):1841-1847.
219. Dalbeth N, Kumar S, Stamp L, Gow P. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol. 2006;33(8):1646-1650.
220. Vazquez-Mellado J, Morales EM, Pacheco-Tena C, Burgos-Vargas R. Relation between adverse events associated with allopurinol and renal function in patients with gout. Ann Rheum Dis. 2001;60(10): 981-983.
221. Ifudu O, Tan CC, Dulin AL, Delano BG, Friedman EA. Gouty arthritis in end-stage renal disease: clinical course and rarity of new cases. Am J Kidney Dis. 1994;23(3):347-351.
222. Schreiner O, Wandel E, Himmelsbach F, Galle PR, Marker-Hermann E. Reduced secretion of proinfammatory cytokines of monosodium urate crystal-stimulated monocytes in chronic renal failure: an explanation for infrequent gout episodes in chronic renal failure patients? Nephrol Dial Transplant. 2000;15(5):644-649.
223. Garg J P, Chasan-Taber S, Blair A, et al. Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trial. Arthritis Rheum. 2005;52(1):290-295.
224. Stamp L, Ha L, Searle M, O'Donnell J, Frampton C, Chapman P. Gout in renal transplant recipients. Nephrology (Carlton). 2006;11(4): 367-371.
225. Stamp L, Searle M, O'Donnell J, Chapman P. Gout in solid organ transplantation: a challenging clinical problem. Drugs. 2005;65(18): 2593-2611.
226. Siegenthaler-Zuber G. Which uric acid value is in need of treatment?. Schweiz Med Wochenschr. 1976;106(14):487-491.
227. Liang MH, Fries JF. Asymptomatic hyperuricemia: the case for conservative management. Ann Intern Med. 1978;88(5):666-670.
228. Dawson J, Quinn T, Walters M. Uric acid reduction: a new paradigm in the management of cardiovascular risk? Curr Med Chem. 2007;14(17): 1879-1886.
229. Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxo-stat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and effcacy in patients with gout. Arthritis Rheum. 2005;52(3): 916-923.
230. Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353(23):2450-2461.
231. Febuxostat Phase 3 Clinical Trials Study NCT00174915. Takeda Pharmaceuticals; 2009. http://clinicaltrials.gov/ct2/show/results/NCT00174915?term=gout&rank=9§=X6015#outcome1. Accessed 2010 Jun 21.
232. Terkeltaub RA. Clinical practice. Gout. N Engl J Med. 2003;349(17): 1647-1655.
233. Reinders MK, van Roon EN, Jansen TL, et al. Effcacy and toler-ability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. Ann Rheum Dis. 2009;68(1):51-56.
234. Lee MH, Graham GG, Williams KM, Day RO. A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients? Drug Saf. 2008;31(8):643-665.
235. Takahashi S, Moriwaki Y, Yamamoto T, Tsutsumi Z, Ka T, Fukuchi M. Effects of combination treatment using anti-hyperuricaemic agents with fenofbrate and/or losartan on uric acid metabolism. Ann Rheum Dis. 2003;62(6):572-575.
236. Terkeltaub R. Gout. Novel therapies for treatment of gout and hyperuricemia. Arthritis Res Ther. 23 2009;11(4):236.
237. Lasko B, Sheedy B, Hingorani V, et al. RDEA594, a novel uricosuric agent, Significantly reduced serum urate levels and was well tolerated in a phase 2a pilot study in hyperuricemic gout patients. 2009 American College of Rheumatology Annual Scientifc Meeting. Philadelphia, PA; 2009.
238. Ardea Biosciences Announces positive results from a Phase 1 Study of RDEA594. Medical News Today 2009; http://www.medicalnewstoday.com/articles/135285.php. Accessed 2010 Aug 30.